Original Source(s)
Related Content
FDA Expands Test for Gastric and Esophageal Cancers
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
-
2 min
Four Patterns in End-of-Life Decline?
International cohort study found physical function declined most rapidly before mortality, while socioeconomic status was associated with more favorable multidomain trajectories.
July 21, 2026
-
4 min